Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
about
Exploiting HIV-1 protease and reverse transcriptase cross-resistance information for improved drug resistance prediction by means of multi-label classificationHIV-1 drug resistance and resistance testing.Data-intensive analysis of HIV mutations.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.A uniquely prevalent nonnucleoside reverse transcriptase inhibitor resistance mutation in Russian subtype A HIV-1 viruses.Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea.Characterization of two HIV-1 infectors during initial antiretroviral treatment, and the emergence of phenotypic resistance in reverse transcriptase-associated mutation patterns.Phenotype, Genotype, and Drug Resistance in Subtype C HIV-1 InfectionResistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection.A simple and cost-saving phenotypic drug susceptibility testing of HIV-1.The connection domain mutation N348I in HIV-1 reverse transcriptase enhances resistance to etravirine and rilpivirine but restricts the emergence of the E138K resistance mutation by diminishing viral replication capacity.Antiviral drug discovery: broad-spectrum drugs from nature.A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.Genetic Variability of HIV-1 for Drug Resistance Assay Development.Ultra-Deep Sequencing Analysis on HIV Drug-Resistance-Associated Mutations Among HIV-Infected Individuals: First Report from the Philippines.HIV-1 genetic diversity and transmitted drug resistance frequency among Iranian treatment-naive, sexually infected individuals.Etravirine and Rilpivirine Drug Resistance Among HIV-1 Subtype C Infected Children Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens in South India.Correlates of infection and molecular characterization of blood-borne HIV, HCV, and HBV infections in HIV-1 infected inmates in Italy: An observational cross-sectional study.Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.Profile of disposition, tissue distribution and excretion of the novel anti-human immunodeficiency virus (HIV) agent W-1 in rats.Prevalence of HIV-1 pre-treatment drug resistance in a southern province of Iran, 2016-2017.Human Immunodeficiency Virus Type 1 Drug Resistance Mutations Update.High prevalence of HIV-1 transmitted drug-resistance mutations from proviral DNA massively parallel sequencing data of therapy-naïve chronically infected Brazilian blood donors.Switching from tenofovir/emtricitabine and nevirapine to a tenofovir/emtricitabine/rilpivirine single-tablet regimen in virologically suppressed, HIV-1-infected subjects.Computational development of rubromycin-based lead compounds for HIV-1 reverse transcriptase inhibition.Identification of cytochrome P450s involved in the metabolism of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1) using human recombinant enzymes and rat liver microsomes in vitro.Molecular Epidemiology of HIV-1 virus in Puerto Rico: Novel Cases of HIV-1 Subtype C, D and CRF-24BG.
P2860
Q28273800-86F1E500-1BEB-4417-B41A-8A43D35F1E6EQ30245693-6C2D2848-1ED1-44DB-9491-D1F15DA310FEQ30887525-24574AB0-DD20-4EFD-BF8A-A5C7041DDE02Q35105844-145E9D4B-1597-4808-8BAD-EED0E3ADE9BDQ35370552-E3FA06BF-7F60-4F7D-AEB7-B63875D81B7CQ35497950-3AF88D7E-C21D-46BF-BE69-410E847653EDQ36292765-BBA03F58-A67E-4DE5-925C-B1200C7D3EC3Q36401516-1D5EC850-73C2-4F26-BE40-2756E273D808Q36744634-E9753A9A-156E-4ACC-BEFB-12EDFFAD76C9Q37264500-D505CDFC-146C-4B52-B14D-A5375D75E2FBQ37547275-55914391-CA1E-4C12-B995-74B4ACB13AE2Q38260235-EB31B5CD-8026-4234-A13D-89AD456784E2Q38739986-3851A538-29BA-49BA-A499-6A85B5B4E116Q38745545-3C0B8E6F-4010-47DA-80FA-9D2DF7CC1F76Q38751410-FA756F42-B13E-43A7-9B35-C950C54E159DQ38759542-8FD172B2-5D4B-4403-BE73-DD479288A0CEQ38792785-FEE542B2-EDC6-411E-9543-FE4763F96425Q40446769-D98087E0-5FB4-4308-BAAE-E9A59B3B55ECQ40688534-92EEC18F-1004-40B3-9349-0DA75026FCE6Q40708931-F4C7676E-2717-4480-8E18-83167E11D45EQ41923120-8EE5B661-06A5-49B8-B7F8-9D92F7848A92Q41926589-76068B72-DF9D-4FA6-A1CF-7613F93F1992Q41929325-8F8FA422-ACDE-4169-B0A6-10B8CC834808Q42211662-0882C73A-E09C-4CD1-88E3-C51EC3FB9652Q42739347-4B8F5810-122E-4FC5-B833-EA77E2685E7DQ51031739-30AB18F1-6E06-486F-B0BA-7FF884BFB9F6Q52586895-2DDEF6D3-E3C1-435F-AF75-B595D48F3A3C
P2860
Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Non-nucleoside reverse transcr ...... genotypic resistance testing.
@en
Non-nucleoside reverse transcriptase inhibitor
@nl
type
label
Non-nucleoside reverse transcr ...... genotypic resistance testing.
@en
Non-nucleoside reverse transcriptase inhibitor
@nl
prefLabel
Non-nucleoside reverse transcr ...... genotypic resistance testing.
@en
Non-nucleoside reverse transcriptase inhibitor
@nl
P2093
P2860
P356
P1476
Non-nucleoside reverse transcr ...... genotypic resistance testing.
@en
P2093
Dennis Israelski
Edwin Dejesus
George L Melikian
Gregory K Robbins
Jeffrey Burack
Jonathan Taylor
Kirsten White
Kristin Razzeca
Paolo Troia
Robert W Shafer
P2860
P356
10.1093/JAC/DKT316
P407
P577
2013-08-09T00:00:00Z